Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20614636 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CYP2C9CYP2C19MEN1KMT2A | |
| SCHEMBL1362640 | 0.83 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL20614632 | 0.76 | ALDH1A1 (0.37) | ALDH1A1CYP2C9CYP2C19MEN1KMT2A | |
| SCHEMBL11682570 | 0.74 | PKM (0.31) | — | |
| SCHEMBL24828766 | 0.73 | FDPS (0.33) | ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL22919805 | 0.73 | ALDH1A1 (0.32) | ALDH1A1CYP2C9CYP2C19MEN1KMT2A | |
| SCHEMBL22063824 | 0.73 | FDPS (0.33) | ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL6967265 | 0.71 | LMNA (0.32) | KMT2A | |
| SCHEMBL15026061 | 0.71 | ALDH1A1 (0.41) | ALDH1A1CYP2C9CYP2C19KMT2A | |
| SCHEMBL22702838 | 0.71 | ALDH1A1 (0.41) | ALDH1A1CYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541052-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-01-03 | — | — | US | disclosed |
| US-20210023084-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2021-01-28 | — | — | US | disclosed |
| US-10835534-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-11-17 | — | — | US | disclosed |
| US-20200179385-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2020-06-11 | — | — | US | disclosed |
| US-10555945-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-02-11 | — | — | US | disclosed |
| US-20190000849-A1 | NOVEL COMPOUNDS | AUTIFONY THERAPEUTICS LIMITED | 2019-01-03 | — | — | US | disclosed |
| US-20180036308-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2018-02-08 | — | — | US | disclosed |
| US-9833452-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9833452-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20160317537-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2016-11-03 | — | — | US | disclosed |
| US-9422272-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-08-23 | — | — | US | disclosed |
| US-20150336936-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336936-A1 | NOVEL COMPOUNDS | KCNN3, KCNN2, KCNN1 | ALDH1A1 1903/4885CYP2C9 1444/4885CYP2C19 1488/4885 |
| US-20190000849-A1 | NOVEL COMPOUNDS | KCNN3, KCND3, KCNA3 | ALDH1A1 2130/4885CYP2C9 1671/4885CYP2C19 1386/4885 |
| US-10835534-B2 | Compounds | KCNN3, KCNA3, KCNQ3 | ALDH1A1 1657/4885CYP2C9 760/4885CYP2C19 747/4885 |
| US-20160317537-A1 | NOVEL COMPOUNDS | KCNN3, KCNN2, KCNN1 | ALDH1A1 1903/4885CYP2C9 1444/4885CYP2C19 1488/4885 |
| US-10555945-B2 | Compounds | KCNN3, KCNA3, KCNQ3 | ALDH1A1 1657/4885CYP2C9 760/4885CYP2C19 747/4885 |
| US-20200179385-A1 | NOVEL COMPOUNDS | KCNN3, KCND3, KCNA3 | ALDH1A1 2130/4885CYP2C9 1671/4885CYP2C19 1386/4885 |
| US-20210023084-A1 | NOVEL COMPOUNDS | KCNN3, KCND3, KCNA3 | ALDH1A1 2130/4885CYP2C9 1671/4885CYP2C19 1386/4885 |
| US-11541052-B2 | Compounds | KCNN3, KCNA3, KCNQ3 | ALDH1A1 1657/4885CYP2C9 760/4885CYP2C19 747/4885 |
| US-20180036308-A1 | NOVEL COMPOUNDS | CYFIP1, CYFIP2, ZFX | ALDH1A1 3841/4885CYP2C9 4788/4885CYP2C19 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.